Skip to search formSkip to main contentSkip to account menu

niravoline

A kappa-opioid receptor agonist with edema relieving activity. Niravoline inhibits the scretion of the antiduretic hormone vasopressin thereby… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzeneacetamidesPyrrolidines

Narrower (1)

RU 51599

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis.
BACKGROUND/AIMS In patients with cirrhosis, decreased renal water excretion is a common complication. Niravoline (RU51599), a… 
2000
2000
Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.
Water retention in experimental cirrhosis can be reversed by blocking V(2)-vasopressin (AVP) receptors with the nonpeptide… 
2000
2000
Aquaretic effects of niravoline, a κ-opioid agonist, in patients with cirrhosis
1999
1999
Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
kappa-Opioid receptor agonists (niravoline) or nonpeptide antidiuretic hormone (ADH) V2 receptor antagonists (OPC-31260) possess… 
1998
1998
Effects of niravoline (RU 51599), a selective kappa-opioid receptor agonist on intracranial pressure in gradually expanding extradural mass lesion.
It has recently been reported that kappa-opioid receptor agonists inhibit antidiuretic hormone secretion and promote water… 
1997
1997
The kappa opioid agonist niravoline decreases brain edema in the mouse middle cerebral artery occlusion model of stroke.
The effect of niravoline (RU 51599), a kappa opioid receptor agonist with water diuretic properties, was assessed on the… 
Highly Cited
1997
Highly Cited
1997
Novel developments with selective, non-peptidic kappa-opioid receptor agonists.
Despite the recent introduction of a number of new compounds, there has of late been a cooling of interest by pharmaceutical… 
1996
1996
Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers.
We noninvasively investigated the effects of a single 30-min i.v. infusion of a 2-mg dose of niravoline, a new selective kappa… 
1996
1996
Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis
Because renal water retention is a complication of cirrhosis, niravoline (RU 51,599), a novel kappa (κ) opioid receptor agonist… 
1996
1996
Disparate expression of the AVP gene in Sabra hypertension-prone and hypertension-resistant rats.
We recently re-inbred the original colony of SBH-SBN rats, a model of salt-induced hypertension. In the course of phenotyping the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)